Shanghai Rendu Biotechnology Co. Ltd. A Asset Resilience Ratio
Shanghai Rendu Biotechnology Co. Ltd. A asset resilience ratio. Shanghai Rendu Biotechnology Co. Ltd. A (688193) has an Asset Resilience Ratio of 70.50% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shanghai Rendu Biotechnology Co. Ltd. A liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Shanghai Rendu Biotechnology Co. Ltd. A (2019–2025)
Asset resilience ratio of Shanghai Rendu Biotechnology Co. Ltd. A from 2019 to 2025. This chart shows how Shanghai Rendu Biotechnology Co. Ltd. A's Asset Resilience Ratio has changed over time. Read Shanghai Rendu Biotechnology Co. Ltd. A balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Rendu Biotechnology Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Shanghai Rendu Biotechnology Co. Ltd. A balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥693.75 Million | 70.5% |
| Total Liquid Assets | CN¥693.75 Million | 70.50% |
Asset Resilience Insights
- Very High Liquidity: Shanghai Rendu Biotechnology Co. Ltd. A maintains exceptional liquid asset reserves at 70.50% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Rendu Biotechnology Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Shanghai Rendu Biotechnology Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 15.78% |
|
Check Cap Ltd
NASDAQ:CHEK |
Diagnostics & Research | 70.29% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
Shanghai Rendu Biotechnology Co. Ltd. A Asset Resilience Ratio by Year (2019–2025)
Shanghai Rendu Biotechnology Co. Ltd. A asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Shanghai Rendu Biotechnology Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 70.04% | CN¥693.47 Million ≈ $101.48 Million |
CN¥990.17 Million ≈ $144.89 Million |
+18.65pp |
| 2024-12-31 | 51.39% | CN¥510.96 Million ≈ $74.77 Million |
CN¥994.36 Million ≈ $145.51 Million |
+46.63pp |
| 2023-12-31 | 4.76% | CN¥50.21 Million ≈ $7.35 Million |
CN¥1.05 Billion ≈ $154.34 Million |
-44.01pp |
| 2022-12-31 | 48.77% | CN¥530.98 Million ≈ $77.70 Million |
CN¥1.09 Billion ≈ $159.31 Million |
+31.60pp |
| 2019-12-31 | 17.17% | CN¥32.12 Million ≈ $4.70 Million |
CN¥187.07 Million ≈ $27.37 Million |
-- |
About Shanghai Rendu Biotechnology Co. Ltd. A
Shanghai Rendu Biotechnology Co., Ltd. engages in the research, development, production, and sales of RNA molecular diagnostic technology and products. It offers products in the areas of reproductive health, bloodborne infections, respiratory infections, enterovirus infections, cancer early detection, and other areas; and AutoSAT, SuperSAT, and ultrasonic homogenizer. The company was founded in 2… Read more